República Txeca - txec - SUKL (Státní ústav pro kontrolu léčiv)

the simple pharma company limited, dublin array - 1422 testosteron - transdermální gel - 20mg/g - testosteron

República Txeca - txec - SUKL (Státní ústav pro kontrolu léčiv)

curium netherlands b.v., petten array - 9673 chlorid thallnÝ-(201tl) - injekční roztok - 37mbq/ml - chlorid thallnÝ-(201tl)

Unió Europea - txec - EMA (European Medicines Agency)

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - cytostatika - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Unió Europea - txec - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - infekce dýchacích syncyciálních virů - vakcíny - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. použití této vakcíny musí být v souladu s oficiálními doporučeními.

Unió Europea - txec - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukemie, myeloid - antineoplastická činidla - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Unió Europea - txec - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycythemia vera - imunostimulancia, - besremi je indikován jako monoterapie u dospělých pro léčbu po polycytemii vera bez symptomatická splenomegalie.

Unió Europea - txec - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anémie, kosáčková buňka - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Unió Europea - txec - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Unió Europea - txec - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastická činidla - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Unió Europea - txec - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (jako fosfát) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastická činidla - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. po polycytemii vera (pv)přípravek jakavi je indikován k léčbě dospělých pacientů s po polycytemii vera, kteří jsou rezistentní na léčbu nebo s intolerancí hydroxymočovina. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.